Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y3I1

UPID:
FBX7_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9Y3I1; B4DNB3; B4DWX5; Q5TGC4; Q5TI86; Q96HM6; Q9UF21; Q9UKT2

BACKGROUND:
The F-box only protein 7 is integral to the SCF E3 ubiquitin-protein ligase complex, mediating the degradation of proteins involved in cell cycle and proliferation. It plays a significant role in mitophagy by promoting the ubiquitination of mitochondrial fusion protein MFN1 and the proteasomal subunit PSMA2, thereby influencing cellular homeostasis and the NF-kappa-B signaling pathway.

THERAPEUTIC SIGNIFICANCE:
Linked to Parkinson disease 15, characterized by tremor, bradykinesia, and rigidity, F-box only protein 7's involvement in neurodegeneration highlights its potential as a target for therapeutic intervention. Exploring its function and pathway could lead to novel treatments for neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.